
|Articles|January 13, 2022
OKRA.ai Extends Collaboration with Bristol Myers Squibb
Advertisement
OKRA.ai, a provider of Artificial Intelligence (AI) driven analytics for global life sciences, today announced that it is extending its collaboration with Bristol Myers Squibb to leverage OKRA’s AI Technology to support future customer engagement. This collaboration, which started in the UK in 2018 has proven to be very successful in bringing together multiple data sources and generating intelligent insights for commercial teams whilst delivering unparalleled levels of automation for the company. In 2021 OKRA.ai and Bristol Myers Squibb expanded use of the system to new markets and will continue to work together and explore further expansion opportunities in 2022.
Read more about the collaboration
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Who Pays for Tariff Driven Input Cost Increases?
2
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
3
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
4
The Shift Towards Globally Sourced Innovation
5




